Virtual Library
Start Your Search
J. Polanska
Author of
-
+
P1.06 - Poster Session/ Screening and Early Detection (ID 218)
- Event: WCLC 2015
- Type: Poster
- Track: Screening and Early Detection
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.06-012 - Components of Serum Peptidome Can Differentiate between Healthy Controls and Patients with Early Stage Lung Cancer (ID 915)
09:30 - 09:30 | Author(s): J. Polanska
- Abstract
Background:
Screening with low-dose computed tomography of high-risk group for lung cancer development allows for early detection of malignancy in a minor proportion of subjects and leads to improved outcomes. Implementation of complementary minimally-invasive molecular markers for more efficient pre-selection of candidates for imaging tests or help to further define detected changes is a rational way to further improve efficacy of such screening. Here we aimed to identify features of serum peptidome that could be used for differentiation of individuals with early lung cancer from other participants of lung cancer screening program.
Methods:
Blood samples were collected during lung cancer screening program performed in Pomerania district (Poland). MALDI-ToF mass spectrometry was used to characterize the low-molecular-weight fraction of serum proteome in the 800-14,000 Da range (i.e. endogenous serum peptidome). The analysis was performed in a group of 100 lung cancer patients (with early stage lung cancer diagnosed without clinical symptoms during the screening program or through routine diagnostic procedures) and a matched group of 300 controls (participants of the screening without malignancy).
Results:
Components of mass spectra were detected and specific features allowing differentiation of cancer cases were identified. The first group of 50 cancer cases and 150 matched controls was used to built and test multi-component peptide signature for cancer classification; obtained classifier showed about 70% specificity and sensitivity. The signature was validated in the second group of independently analyzed samples (50 cancer cases and 150 matched controls); the classifier performed well and the total number of misclassifications was below 25%.
Conclusion:
MALDI-based profiling of serum peptidome allowed identification of components differentiating patients with early stage lung cancer from healthy individuals. Hence, biomarker based on serum peptide signature has a potential applicability for early detection of lung cancer.
